ATE457312T1 - Azaindole als hemmstoffe von c-jun n-terminalen kinasen - Google Patents

Azaindole als hemmstoffe von c-jun n-terminalen kinasen

Info

Publication number
ATE457312T1
ATE457312T1 AT03709986T AT03709986T ATE457312T1 AT E457312 T1 ATE457312 T1 AT E457312T1 AT 03709986 T AT03709986 T AT 03709986T AT 03709986 T AT03709986 T AT 03709986T AT E457312 T1 ATE457312 T1 AT E457312T1
Authority
AT
Austria
Prior art keywords
jun
azaindoles
inhibitors
terminal kinases
compounds
Prior art date
Application number
AT03709986T
Other languages
English (en)
Inventor
Piotr Graczyk
Hirotoshi Numata
Gurpreet Bhatia
Darren P Medland
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207488A external-priority patent/GB0207488D0/en
Priority claimed from GB0300400A external-priority patent/GB0300400D0/en
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE457312T1 publication Critical patent/ATE457312T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT03709986T 2002-03-28 2003-03-17 Azaindole als hemmstoffe von c-jun n-terminalen kinasen ATE457312T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0207488A GB0207488D0 (en) 2002-03-28 2002-03-28 Inhibitors
GB0300400A GB0300400D0 (en) 2003-01-08 2003-01-08 JNK inhibitors
PCT/GB2003/001115 WO2003082869A1 (en) 2002-03-28 2003-03-17 Azaindoles as inhibitors of c-jun n-terminal kinases

Publications (1)

Publication Number Publication Date
ATE457312T1 true ATE457312T1 (de) 2010-02-15

Family

ID=28676497

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03709986T ATE457312T1 (de) 2002-03-28 2003-03-17 Azaindole als hemmstoffe von c-jun n-terminalen kinasen

Country Status (11)

Country Link
US (1) US7291630B2 (de)
EP (1) EP1490365B1 (de)
JP (1) JP2005534619A (de)
KR (1) KR20050013534A (de)
CN (1) CN100338062C (de)
AT (1) ATE457312T1 (de)
AU (1) AU2003214414B2 (de)
CA (1) CA2479205A1 (de)
DE (1) DE60331219D1 (de)
IL (1) IL164082A0 (de)
WO (1) WO2003082869A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
WO2003082868A1 (en) 2002-03-28 2003-10-09 Eisai Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
CN100338062C (zh) 2002-03-28 2007-09-19 卫材株式会社 作为c－Jun N－末端激酶抑制剂的氮杂吲哚类化合物
US7432375B2 (en) 2003-03-06 2008-10-07 Eisai R & D Management Co., Ltd. JNK inhibitors
GB0305142D0 (en) * 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
EP1628975A2 (de) 2003-05-16 2006-03-01 Eisai Co., Ltd. Jnk inhibitoren
EP1696920B8 (de) 2003-12-19 2015-05-06 Plexxikon Inc. Verbindungen und verfahren zur entwicklung von ret-modulatoren
GB0405055D0 (en) * 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
KR20070002081A (ko) 2004-04-02 2007-01-04 버텍스 파마슈티칼스 인코포레이티드 Ｒｏｃｋ 및 기타 단백질 키나아제의 억제제로서 유용한아자인돌
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
EP1765819B1 (de) * 2004-06-30 2014-03-12 Vertex Pharmaceuticals Inc. Als protein-kinase-inhibitoren nutzbare azaindole
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CA2573573A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
JP2008508303A (ja) 2004-07-27 2008-03-21 エスジーエックス ファーマシューティカルズ、インコーポレイテッド ピロロ−ピリジンキナーゼモジュレーター
EP1807425B1 (de) * 2004-10-27 2014-07-30 Janssen Pharmaceutica NV Pyridinimidazole und aza-indole als progesteronrezeptor-modulatoren
KR20080027775A (ko) 2005-05-17 2008-03-28 플렉시콘, 인코퍼레이티드 피롤(２,３-ｂ)피리딘 유도체 단백질 키나제 억제제
WO2006125324A1 (en) 2005-05-27 2006-11-30 Queen's University At Kingston Treatment of protein folding disorders
CN102603581B (zh) 2005-06-22 2015-06-24 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
GB0516156D0 (en) * 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
US20090306126A1 (en) * 2006-05-22 2009-12-10 Astrazeneca Ab Indole Derivatives
JP4857071B2 (ja) * 2006-10-12 2012-01-18 潤平 笹部 筋萎縮性側策硬化症（ａｌｓ）の検出方法
JP2010510177A (ja) * 2006-11-17 2010-04-02 クイーンズ ユニバーシティ アット キングストン タンパク質フォールディング障害を治療するための化合物および方法
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CR20170089A (es) 2009-04-03 2017-07-17 Plexxikon Inc Composiciones del acido propano-1--sulfonico {3-[5-(4-cloro-fenil)-1h-pirrolo [2,3-b] piridina-3-carbonil] -2,4-difluoro-fenil}-amida y el uso de las mismas
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2011109932A1 (en) 2010-03-09 2011-09-15 F.Hoffmann-La Roche Ag Novel process for the manufacture of 5-halogenated-7-azaindoles
MA34948B1 (fr) 2011-02-07 2014-03-01 Plexxikon Inc Composes et procedes de modulation de kinase, et leurs indications
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP3495359A1 (de) 2013-02-04 2019-06-12 Janssen Pharmaceutica NV Flap-modulatoren
TWI644899B (zh) * 2013-02-04 2018-12-21 健生藥品公司 Ｆｌａｐ調節劑
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
CA2903293C (en) 2013-03-15 2020-10-13 Plexxikon Inc. Heterocyclic compounds and uses thereof
US9206188B2 (en) * 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
WO2015089192A1 (en) * 2013-12-11 2015-06-18 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
JP2017505346A (ja) * 2014-02-12 2017-02-16 アイティーオス セラペウティクス 新規な３−（インドール−３−イル）−ピリジン誘導体、医薬組成物、および使用方法
MD20160118A2 (ro) 2014-05-15 2017-04-30 Iteos Therapeutics Derivaţi ai pirolidin-2,5-dionei, compoziţii farmaceutice şi metode de utilizare ca inhibitori ai IDO1
EP3271354A1 (de) 2015-03-17 2018-01-24 Pfizer Inc Neuartige 3-indol-substituierte derivate, pharmazeutische zusammensetzungen und verfahren zur verwendung
US10544095B2 (en) 2015-08-10 2020-01-28 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use
EP3596075B1 (de) 2017-03-15 2023-10-11 F. Hoffmann-La Roche AG Azaindole als inhibitoren von hpk1
CN111194318B (zh) 2017-10-13 2023-06-09 Opna生物公司 用于调节激酶的化合物固体形式

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009598A1 (en) * 1990-01-05 1991-07-11 Pfizer Inc. Azaoxindole derivatives
MX9305947A (es) * 1992-09-29 1994-06-30 Smithkline Beecham Plc Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
ATE182332T1 (de) * 1994-06-16 1999-08-15 Pfizer Pyrazolo und pyrrolopyridine
FR2732969B1 (fr) 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
ATE387448T1 (de) 1998-12-17 2008-03-15 Hoffmann La Roche 4,5-pyrazinoxindole als proteinkinasehemmer
EP1149093A1 (de) 1998-12-17 2001-10-31 F. Hoffmann-La Roche Ag 4-aryloxindolen als inhibitoren von jnk proteinkinasen
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
AR028475A1 (es) * 1999-04-22 2003-05-14 Wyeth Corp Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
JP2003532626A (ja) 1999-08-19 2003-11-05 シグナル ファーマシューティカルズ， インコーポレイテッド Ｊｎｋ阻害剤としてのピラゾロアントロン及びその誘導体並びにそれらの組成物
US6642375B2 (en) * 1999-12-07 2003-11-04 Fuji Photo Film Co., Ltd. Fluorescent substances
CN1615873A (zh) * 1999-12-24 2005-05-18 阿文蒂斯药物有限公司 氮杂吲哚类化合物
ATE387199T1 (de) * 2000-01-06 2008-03-15 Merck Frosst Canada Ltd Neue substanzen und verbindungen als protease- inhibitoren
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
CN100338062C (zh) 2002-03-28 2007-09-19 卫材株式会社 作为c－Jun N－末端激酶抑制剂的氮杂吲哚类化合物

Also Published As

Publication number Publication date
CA2479205A1 (en) 2003-10-09
DE60331219D1 (de) 2010-03-25
KR20050013534A (ko) 2005-02-04
US20060111390A1 (en) 2006-05-25
EP1490365B1 (de) 2010-02-10
WO2003082869A1 (en) 2003-10-09
US7291630B2 (en) 2007-11-06
AU2003214414B2 (en) 2008-10-09
CN100338062C (zh) 2007-09-19
EP1490365A1 (de) 2004-12-29
CN1649869A (zh) 2005-08-03
AU2003214414A1 (en) 2003-10-13
IL164082A0 (en) 2005-12-18
JP2005534619A (ja) 2005-11-17

Similar Documents

Publication Publication Date Title
ATE457312T1 (de) Azaindole als hemmstoffe von c-jun n-terminalen kinasen
ATE374200T1 (de) 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
ATE297394T1 (de) Jun kinase inhibitoren
ATE468337T1 (de) 3,5-disubstituierte 1h-pyrrolo ä2,3-bü pyridine als jnk-inhibitoren
WO2004078756A3 (en) Jnk inhibitors
GB0516156D0 (en) JNK inhibitors
WO2004101565A3 (en) Jnk inhibitors
NO20064852L (no) Azaindoler som er nyttige som inhibitorer av jak og andre proteinkinaser
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
NO20061197L (no) Proteasominhibitorer og fremgangsmater for anvendelse av samme
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
NO20053792L (no) Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
DK1846424T3 (da) Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf
HK1089153A1 (en) Proteasome inhibitors and methods of using the same
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
MX2009010034A (es) Pirimidodiazepinas sustituidas utiles inhibidores de la plk1.
UA87494C2 (en) Azaindoles useful as inhibitors of jak and other protein kinases
TW200740808A (en) Inhibiteurs de proteines kinases
MY162518A (en) Proteasome inhibitors and methods of using the same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties